Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
January 04, 2021 at 09:15 AM EST
ENGLEWOOD, Colo., Jan. 4, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced an update on the launch of a new global clinical trial for intravenous ("IV") treatment of COVID-19 with Ampion and provided updates on its ongoing U.S. trial for inhalation treatment of COVID-19.
In vitro, Ampion interrupts the hyper-active immune response, known as the cytokine storm, which is directly associated with the more serious symptoms of COVID-19. The benefit of this effect from Ampion is currently being studied in multiple human clinical trials. The latest updates on these trials include:
"While the vaccine will hopefully help many people avoid the more serious complications of COVID-19, the rollout of vaccines will take time and is unlikely to ever reach 100% of the public," said Michael Macaluso, Chairman and Chief Executive Officer of Ampio Pharmaceuticals. "We will no doubt continue to need treatments to provide the essential relief and improve outcomes for patients. We are especially excited to begin the testing of Ampion for COVID-19 in an outpatient setting."
About Ampio Pharmaceuticals
Forward Looking Statements
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-provides-update-on-clinical-trials-for-ampion-treatment-of-covid-19-patients-301199940.html
SOURCE Ampio Pharmaceuticals, Inc.